Vyhledat

66 Result(s)
Seřadit podle

empulse-trial-benefit-acute-heart-failure

empulse-trial-benefit-acute-heart-failure

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
emperor-preserved-heart-failure-full-data

emperor-preserved-heart-failure-full-data

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
emperor-preserved-kidney-subanalysis

emperor-preserved-kidney-subanalysis

New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Clinical-phase2-trials-NASH-and-obesity

Clinical-phase2-trials-NASH-and-obesity

Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Výzkum a vývoj v rámci péče o pacienty se schizofrenií

Výzkum a vývoj v rámci péče o pacienty se schizofrenií

Na světě žije 24+ mil. lidí se schizofrenií, přesto stále panuje velké nepochopení této nemoci. Klíčovou prioritou je pro nás rozvoj v oblasti včasné diagnostiky a prevence a snaha o rovná práva pro pacienty se schizofrenií.